


Mouse Models of Essential Thrombocythemia (ET) and Myelofibrosis (MF) – Available for Preclinical Studies


Characterisation of the ET Model

Heterozygous $CALR^{del/+}$ mice present with:


- Increased number of platelets (Figure A)



- Reduced number of erythroblasts (Figure B)




- Megakaryocytic hyperplasia (increased clustering and hyperlobated nuclei increased megakaryopoiesis (Figure C))



Characterisation of the MF model

Homozygous $CALR^{del/+}$ mice present with:

- Increased platelets and white cells, and reduced hemoglobin levels (Figure A)
- Splenomegaly (Figure B)
- Increased levels of bone marrow reticulin (indicating bone marrow fibrosis) (Figure C)
- Features that resemble myelofibrotic transformation of ET



Both the ET and MF murine models have been robustly characterised, and are valuable preclinical models available for non-exclusive licensing.

Lead academic

Tony Green

Professor of Haemato-Oncology; Director of the Wellcome – MRC Cambridge Stem Cell Institute

Tony has held multiple academic, clinical and educational leadership roles, both nationally and internationally, has been appointed to visiting professorships at several universities, was elected Fellow of the Academy of Medical Sciences (2001) and President of the European Haematology Association (2015-2017). Recent awards include the Jean Bernard Award by the European Haematology Association (2020) and the Donald Metcalf award by the International Society for Experimental Hematology (2021).



Paper

Mutant calreticulin knock-in mice develop thrombocytosis and myelofibrosis without a stem cell self-renewal advantage, Green et al., Blood, 2018, doi: 10.1182/blood-2017-09-806356.

Banner image: Essential Thrombocythemia, Peripheral Blood, from Ed Uthman via Flickr, [Attribution \(CC BY 2.0\)](#)

Available Technologies

Mouse Models of Essential Thrombocythemia and Myelofibrosis - Available for Preclinical Studies

Researchers at the University of Cambridge have generated fully characterised, conditional knock-in mouse models for essential thrombocythemia (ET) and related myelofibrosis (PMF) that are available to license for preclinical studies.

This mouse line conditionally expresses a mutant Calreticulin with humanized novel C terminus which is found in human patients, under the control of the endogenous mouse locus.

Technology overview

Essential thrombocythemia (ET) and Primary myelofibrosis (MF) are two types of myeloid proliferative neoplasms (MPNs). MPNs are chronic hematologic malignancies that arise in the hematopoietic stem cell compartment and share a variable propensity to transform to acute myeloid leukaemia.

In ET and PMF, 50-60% of patients carry a JAK2 mutation. Of the non-JAK2 mutated patients, 70-80% carry mutations in calreticulin (CALR) which encodes an endoplasmic reticulum chaperone.

Key Features

- Mutant CALR expression results in expansion of immunophenotypic HSCs
- Shows clear differences in the consequences of CALR and JAK2 mutations
- Powerful tool to further dissect mutant CALR contribution to myeloid proliferative neoplasm (MPN) pathogenesis
- Enables screening and preclinical validating of drugs targeting MPN stem cells

ET Model

- Heterozygous CALRdel/+ C57BL/6
- Develops a myeloproliferative phenotype resembling human ET
- Presents with marked thrombocytosis
- Displays increased megakaryopoiesis

PMF Model



- Homozygous CALRdel/del C57BL/6
- Presents with severe thrombocytosis and development of MF
- Presents with an increased white blood cell count and reduced haemoglobin level
- Presents with splenomegaly
- Displays increased BM reticulin level